Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

News Conference News ESC 2024

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

Shelley Wood

September 03, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Conference News EuroPCR 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Caitlin E. Cox

May 15, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News CRT 2023

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Yael L. Maxwell

February 27, 2023

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Conference News TCT 2020

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

Michael O'Riordan

October 19, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

News Conference News CRT 2019

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

Yael L. Maxwell

March 07, 2019

Advertisement

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

OCCUPI: OCT Guidance Improves Outcomes in Complex PCI

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Under ISCHEMIA’s Long Shadow, Cardiologists Ponder Shifting Guidelines, Care

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

ORBITA Absorbed: Principal Investigator Reflects on How Results Have Changed Her Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content